Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Austar LifesciencesAULSF 45 Cash Ratio is 0.19 as of Dec. 2025, which is 10% below its 10-year median of 0.21. GuruFocus rates AULSF with a GF Score™ of 45/100 and a GF Value™ of $0.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 833 Medical Devices & Instruments companies, Austar Lifesciences ranks worse than 84.39% on this metric.
Austar Lifesciences has a Cash Ratio of 0.19. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Austar Lifesciences's Cash Ratio or its related term are showing as below:
AULSF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.11 Med: 0.21 Max: 0.91
Current: 0.19
During the past 13 years, Austar Lifesciences's highest Cash Ratio was 0.91. The lowest was 0.11. And the median was 0.21.
AULSF's Cash Ratio is ranked worse than 84.39% of 833
companies
in the Medical Devices & Instruments industry
Industry Median: 0.96
vs AULSF: 0.19
Austar Lifesciences (OTCPK:AULSF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Austar Lifesciences Cash Ratio Related Terms
Austar Lifesciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a Cash Ratio of 0.19 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Austar Lifesciences and its competitors. This is 10% below median its historical median of 0.21. Over the past decade, Austar Lifesciences' Cash Ratio has ranged from 0.11 to 0.91. According to the industry distribution chart, Austar Lifesciences ranks #703 out of 833 companies in the Medical Devices & Instruments industry, placing it in the top 84.4%.
Is Austar Lifesciences' Cash Ratio too high?
Austar Lifesciences' current Cash Ratio of 0.19 is 10% below median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.91. The Medical Devices & Instruments industry median Cash Ratio is 0.96. Austar Lifesciences' value of 0.19 is 80.2% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #703 out of 833 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Austar Lifesciences has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #703 out of 833 companies for Cash Ratio. This places Austar Lifesciences in the lower half of its industry. The industry median Cash Ratio is 0.96. Austar Lifesciences' value of 0.19 is 80.2% below this benchmark. Historically, Austar Lifesciences' own Cash Ratio has ranged from 0.11 to 0.91 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 0.96, Austar Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.96, based on 833 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current Cash Ratio of 0.19 is 80.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current Cash Ratio is 0.19, which is 10% below median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (AULSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.02 — trading 75% below its estimated fair value. The current Cash Ratio is 0.19, which is 10% below median its 10-year median of 0.21 and 80.2% below the Medical Devices & Instruments industry median of 0.96. Austar Lifesciences' overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Cash Ratio is 0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 75% below its estimated GF Value™ of $0.08.
GuruFocus considers Austar Lifesciences to be Possible Value Trap.
Key valuation signals for AULSF:
Cash Ratio: 0.19 (10% below median its 10-year median of 0.21)
GF Value™: $0.08 vs. price of $0.02 (75% below fair value)
Industry Position: 80.2% below the Medical Devices & Instruments median (#703 of 833)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
45GF Score
Get the complete analysis for AULSF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
